Biologic therapy for ulcerative colitis associated with immune thrombocytopenia. uri icon

Overview

abstract

  • Ulcerative colitis (UC), a subtype of inflammatory bowel disease, occasionally manifests with extraintestinal manifestations. We present a 51-year-old male with refractory UC and immune thrombocytopenia (ITP) resistant to conventional treatments. The introduction of biologics, ustekinumab or adalimumab, resulted in clinical remission of colitis and improvements in platelet count. This case underscores the efficacy of biologics in managing refractory UC associated with ITP, emphasizing their potential to control intestinal inflammation and address concurrent thrombocytopenia, potentially avoiding surgical intervention.

publication date

  • July 31, 2024

Research

keywords

  • Adalimumab
  • Colitis, Ulcerative
  • Purpura, Thrombocytopenic, Idiopathic
  • Ustekinumab

Identity

Scopus Document Identifier

  • 85200109812

Digital Object Identifier (DOI)

  • 10.1007/s12328-024-02022-w

PubMed ID

  • 39085737

Additional Document Info

volume

  • 17

issue

  • 5